Israeli medical technology company TempraMed has launched a device to keep diabetes insulin at a safe temperature constantly, without user intervention, the company has announced.
Follow Israel Hayom on Facebook and Twitter
Insulin is a protein that spoils and degrades in the wrong temperature conditions. From the point of manufacturing up until it is used, insulin needs to be kept between 36° to 46°F. Injecting insulin that has broken down due to time or temperature, results in poor blood sugar control, and in time can lead to increased dosages and sometimes hospitalization for stabilization.
TempraMed's VIVI Cap 1 is FDA registered and CE marked.
TempraMed founder and CEO Ron Nagar said, "After spending years recognizing the endless struggle that people with diabetes have to gain control over blood glucose levels, I noticed that those on insulin, take it for granted that insulin is always the same and at its best. But sadly, that is not the reality, so in order to protect the insulin without adding any hassle we developed this unique device and made it available for all."
